An antibody analysis has identified two biomarkers that can be used to predict the development of…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
An estrogen-based therapy, called indazole chloride (IndCl), was shown to protect against optic nerve damage in a mouse…
Scientists have discovered epigenetic changes in a gene called HTR2A, found only in immune cells isolated from people…
Long-term use of disease-modifying therapies (DMTs) in people with relapsing-remitting multiple sclerosis (RRMS)…
Levels of myelin sheath components called ceramides are altered in the blood of people with…
Exposure to stress before birth can worsen the clinical symptoms of multiple sclerosis (MS) during adulthood, a…
Disability, fatigue, depression, cognitive impairment, and unemployment are primary risk factors for a poor quality of life in people with…
The expansion of chronic white matter lesions in people with relapsing-remitting multiple sclerosis…
Nasal delivery of Rebif’s active ingredient interferon-beta, loaded in carbohydrate-based nanoparticles, reduced disease…
Studied for the first time, Aubagio (teriflunomide) slowed the loss of cortical grey matter and whole-brain…
Lower levels of pro-inflammatory immune signaling proteins were found in the blood of people with…
The use of disease-modifying therapies (DMTs) in adults with multiple…
Adults with active relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri…
Using a two-pronged approach, researchers were able to restore myelin on regenerated nerve fibers in a mouse…
Human placental extract eased clinical symptoms, inflammation, and weight and myelin loss in a mouse model…
In a nationwide survey of cannabis-based therapy use among Americans with multiple sclerosis…
Rituximab, an investigational B-cell depletion therapy that target CD20 to treat people with multiple sclerosis (MS), has significant effects…
Alterations in gut bacteria and bacterial metabolism were found in Japanese people at different stages of multiple…
A comparison of immune cells isolated from identical twins — in which only one of each pair was…
Ocrevus (ocrelizumab) eliminated the immunity, acquired through vaccination, to the varicella-zoster virus — the virus…
A protein known as Gsta4 is critical in the growth and activity of oligodendrocytes, a special type of…
Inflammation drives the loss of brain volume and thinning of the eye’s retina in the first five years…
For the first time, scientists have shown that a protein known as CD36 on the surface of some…
Cigarette smoking and an Epstein–Barr virus infection together represent a significant risk factor for multiple sclerosis (MS), suggesting…
The pro-inflammatory signaling protein interleukin (IL)-17A, which is associated with nerve damage in multiple sclerosis…
A variant of the HLA-DPB1 gene — called HLA-DPB1*04…
A multimedia smartphone application designed to precisely inform about exercise and track physical activity led primary…
Comorbidities such as anxiety and depression are associated with a significantly increased risk of relapse in people with…
Cognitive problems are common in people with multiple sclerosis (MS) but inadequately addressed by disease-modifying therapies, while cognitive rehabilitation…
After repeated exposure to a fragment of the myelin protein — the target of autoimmune attack in…